Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation

This study has been withdrawn prior to enrollment.
(Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell production.)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: March 18, 2009
Last updated: March 3, 2014
Last verified: March 2014
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)